iCo Therapeutics (iCo Therapeutics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Mar. 2021)

View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

iCo Therapeutics's net issuance of preferred for the three months ended in Mar. 2021 was $0.00 Mil. The number is 0, which means that iCo Therapeutics has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

iCo Therapeutics's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2021 was $0.00 Mil.

iCo Therapeutics Net Issuance of Preferred Stock Historical Data

The historical data trend for iCo Therapeutics's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics Net Issuance of Preferred Stock Chart

iCo Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

iCo Therapeutics Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

iCo Therapeutics Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

iCo Therapeutics Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

iCo Therapeutics (iCo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4

Website

http://www.icotherapeutics.com

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines